Molecular pathogenesis of intrahepatic cholangiocarcinoma

Journal of Hepato-Biliary-Pancreatic Sciences

Volumn 22, Issue 2, 2015, Pages 101-113

  Andersen, Jesper B ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Epigenetics; Genomics; Intrahepatic cholangiocarcinoma; Molecular pathology; Somatic alterations and tumor heterogeneity

Indexed keywords

JANUS KINASE; NOTCH RECEPTOR; POLO LIKE KINASE; SONIC HEDGEHOG PROTEIN; STAT PROTEIN; UNTRANSLATED RNA; WNT PROTEIN; TUMOR MARKER;

ARTICLE; BILE DUCT CARCINOMA; CHROMOSOME ABERRATION; EPIGENETICS; GAIN OF FUNCTION MUTATION; HUMAN; MOLECULAR PATHOLOGY; NEXT GENERATION SEQUENCING; SOMATIC MUTATION; TUMOR MICROENVIRONMENT; WNT SIGNALING PATHWAY; BILE DUCT TUMOR; CELL TRANSFORMATION; INTRAHEPATIC BILE DUCT; METABOLISM; PATHOLOGY;

BILE DUCT NEOPLASMS; BILE DUCTS, INTRAHEPATIC; BIOMARKERS, TUMOR; CELL TRANSFORMATION, NEOPLASTIC; CHOLANGIOCARCINOMA; HUMANS;

EID: 84921958175     PISSN: 18686974     EISSN: 18686982     Source Type: Journal    
DOI: 10.1002/jhbp.155     Document Type: Article

References (137)

1. Bridgewater J, Galle PR, Khan SA, Llovet JM, Park JW, Patel T, et-al. Guidelines for the diagnosis and management of intrahepatic cholangiocarcinoma. J Hepatol. 2014; 60: 1268-1289.
2. Bragazzi CM, Cardinale V, Carpino G, Venere R, Semeraro R, Gentile R, et-al. Cholangiocarcinoma: epidemiology and risk factors. Transl Gastrointest Cancer. 2012; 1: 21-23.
3. von Hahn T, Ciesek S, Wegener G, Plentz RR, Weismuller TJ, Wedemeyer H, et-al. Epidemiological trends in incidence and mortality of hepatobiliary cancers in Germany. Scand J Gastroenterol. 2011; 46: 1092-1098.
4. Khan SA, Davidson BR, Goldin RD, Heaton N, Karani J, Pereira SP, et-al. Guidelines for the diagnosis and treatment of cholangiocarcinoma: an update. Gut. 2012; 61: 1657-1669.
5. Everhart JE, Ruhl CE,. Burden of digestive diseases in the United States Part III: liver, biliary tract, and pancreas. Gastroenterology. 2009; 136: 1134-1144.
6. Andersen JB, Thorgeirsson SS,. A perspective on molecular therapy in cholangiocarcinoma: present status and future directions. Future Med (Hepatic Oncology). 2014; 1: 143-157.
7. Valle J, Wasan H, Palmer DH, Cunningham D, Anthoney A, Maraveyas A, et-al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med. 2010; 362: 1273-1281.
8. Kumar M, Zhao X, Wang XW,. Molecular carcinogenesis of hepatocellular carcinoma and intrahepatic cholangiocarcinoma: one step closer to personalized medicine? Cell Biosci. 2011; 1: 5.
9. Razumilava N, Gores GJ,. Classification, diagnosis, and management of cholangiocarcinoma. Clin Gastroenterol Hepatol. 2013; 11: 13-21. e1; quiz e3-4.
10. Palmer WC, Patel T,. Are common factors involved in the pathogenesis of primary liver cancers? A meta-analysis of risk factors for intrahepatic cholangiocarcinoma. J Hepatol. 2012; 57: 69-76.
11. Brandi G, Di Girolamo S, Farioli A, de Rosa F, Curti S, Pinna AD, et-al. Asbestos: a hidden player behind the cholangiocarcinoma increase? Findings from a case-control analysis. Cancer Causes Control. 2013; 24: 911-918.
12. Kumagai S, Kurumatani N, Arimoto A, Ichihara G,. Cholangiocarcinoma among offset colour proof-printing workers exposed to 1,2-dichloropropane and/or dichloromethane. Occup Environ Med. 2013; 70: 508-510.
13. Mavros MN, Economopoulos KP, Alexiou VG, Pawlik TM,. Treatment and prognosis for patients with intrahepatic cholangiocarcinoma: systematic review and meta-analysis. JAMA Surg. 2014; doi: 10.1001/jamasurg.2013.5137.
14. Nowell PC,. The clonal evolution of tumor cell populations. Science. 1976; 194: 23-28.
15. Vakiani E, Janakiraman M, Shen R, Sinha R, Zeng Z, Shia J, et-al. Comparative genomic analysis of primary versus metastatic colorectal carcinomas. J Clin Oncol. 2012; 30: 2956-2962.
16. Campbell PJ, Yachida S, Mudie LJ, Stephens PJ, Pleasance ED, Stebbings LA, et-al. The patterns and dynamics of genomic instability in metastatic pancreatic cancer. Nature. 2010; 467: 1109-1113.
17. Gerlinger M, Rowan AJ, Horswell S, Larkin J, Endesfelder D, Gronroos E, et-al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med. 2012; 366: 883-892.
18. Kreso A, O'Brien CA, van Galen P, Gan OI, Notta F, Brown AM, et-al. Variable clonal repopulation dynamics influence chemotherapy response in colorectal cancer. Science. 2013; 339: 543-548.
19. Cardinale V, Carpino G, Reid L, Gaudio E, Alvaro D,. Multiple cells of origin in cholangiocarcinoma underlie biological, epidemiological and clinical heterogeneity. World J Gastrointest Oncol. 2012; 4: 94-102.
20. Roskams T,. Liver stem cells and their implication in hepatocellular and cholangiocarcinoma. Oncogene. 2006; 25: 3818-3822.
21. Fan B, Malato Y, Calvisi DF, Naqvi S, Razumilava N, Ribback S, et-al. Cholangiocarcinomas can originate from hepatocytes in mice. J Clin Invest. 2012; 122: 2911-2915.
22. Holczbauer A, Factor VM, Andersen JB, Marquardt JU, Kleiner DE, Raggi C, et-al. Modeling pathogenesis of primary liver cancer in lineage-specific mouse cell types. Gastroenterology. 2013; 145: 221-231.
23. Sekiya S, Suzuki A,. Intrahepatic cholangiocarcinoma can arise from Notch-mediated conversion of hepatocytes. J Clin Invest. 2012; 122: 3914-3918.
24. Guest RV, Boulter L, Kendall TJ, Minnis-Lyons SE, Walker R, Wigmore SJ, et-al. Cell lineage tracing reveals a biliary origin of intrahepatic cholangiocarcinoma. Cancer Res. 2014; 74: 1005-1010.
25. Zender S, Nickeleit I, Wuestefeld T, Sorensen I, Dauch D, Bozko P, et-al. A critical role for notch signaling in the formation of cholangiocellular carcinomas. Cancer Cell. 2013; 23: 784-795.
26. Dill MT, Tornillo L, Fritzius T, Terracciano L, Semela D, Bettler B, et-al. Constitutive Notch2 signaling induces hepatic tumors in mice. Hepatology. 2013; 57: 1607-1619.
27. Chen X, Calvisi DF,. Hydrodynamic transfection for generation of novel mouse models for liver cancer research. Am J Pathol. 2014; 184: 912-923.
28. O'Dell MR, Huang JL, Whitney-Miller CL, Deshpande V, Rothberg P, Grose V, et-al. Kras(G12D) and p53 mutation cause primary intrahepatic cholangiocarcinoma. Cancer Res. 2012; 72: 1557-1567.
29. Saborowski A, Saborowski M, Davare MA, Druker BJ, Klimstra DS, Lowe SW,. Mouse model of intrahepatic cholangiocarcinoma validates FIG-ROS as a potent fusion oncogene and therapeutic target. Proc Natl Acad Sci USA. 2013; 110: 19513-19518.
30. Xu X, Kobayashi S, Qiao W, Li C, Xiao C, Radaeva S, et-al. Induction of intrahepatic cholangiocellular carcinoma by liver-specific disruption of Smad4 and Pten in mice. J Clin Invest. 2006; 116: 1843-1852.
31. Andersen JB, Thorgeirsson SS,. Genetic profiling of intrahepatic cholangiocarcinoma. Curr Opin Gastroenterol. 2012; 28: 266-272.
32. Andersen JB, Thorgeirsson SS,. Genomic decoding of intrahepatic cholangiocarcinoma reveals therapeutic opportunities. Gastroenterology. 2013; 144: 687-690.
33. Sia D, Tovar V, Moeini A, Llovet JM,. Intrahepatic cholangiocarcinoma: pathogenesis and rationale for molecular therapies. Oncogene. 2013; 32: 4861-4870.
34. Andersen JB, Spee B, Blechacz BR, Avital I, Komuta M, Barbour A, et-al. Genomic and genetic characterization of cholangiocarcinoma identifies therapeutic targets for tyrosine kinase inhibitors. Gastroenterology. 2012; 142: 1021-1031. e15.
35. Oishi N, Kumar MR, Roessler S, Ji J, Forgues M, Budhu A, et-al. Transcriptomic profiling reveals hepatic stem-like gene signatures and interplay of miR-200c and epithelial-mesenchymal transition in intrahepatic cholangiocarcinoma. Hepatology. 2012; 56: 1792-1803.
36. Sia D, Hoshida Y, Villanueva A, Roayaie S, Ferrer J, Tabak B, et-al. Integrative molecular analysis of intrahepatic cholangiocarcinoma reveals 2 classes that have different outcomes. Gastroenterology. 2013; 144: 829-840.
37. Wang P, Dong Q, Zhang C, Kuan PF, Liu Y, Jeck WR, et-al. Mutations in isocitrate dehydrogenase 1 and 2 occur frequently in intrahepatic cholangiocarcinomas and share hypermethylation targets with glioblastomas. Oncogene. 2013; 32: 3091-3100.
38. McKay SC, Unger K, Pericleous S, Stamp G, Thomas G, Hutchins RR, et-al. Array comparative genomic hybridization identifies novel potential therapeutic targets in cholangiocarcinoma. HPB (Oxford). 2011; 13: 309-319.
39. Woo HG, Park ES, Cheon JH, Kim JH, Lee JS, Park BJ, et-al. Gene expression-based recurrence prediction of hepatitis B virus-related human hepatocellular carcinoma. Clin Cancer Res. 2008; 14: 2056-2064.
40. Seok JY, Na DC, Woo HG, Roncalli M, Kwon SM, Yoo JE, et-al. A fibrous stromal component in hepatocellular carcinoma reveals a cholangiocarcinoma-like gene expression trait and epithelial-mesenchymal transition. Hepatology. 2012; 55: 1776-1786.
41. Cazals-Hatem D, Rebouissou S, Bioulac-Sage P, Bluteau O, Blanche H, Franco D, et-al. Clinical and molecular analysis of combined hepatocellular-cholangiocarcinomas. J Hepatol. 2004; 41: 292-298.
42. Fujii H, Zhu XG, Matsumoto T, Inagaki M, Tokusashi Y, Miyokawa N, et-al. Genetic classification of combined hepatocellular-cholangiocarcinoma. Hum Pathol. 2000; 31: 1011-1017.
43. Murata M, Miyoshi Y, Iwao K, Wada H, Shibata K, Tateishi H, et-al. Combined hepatocellular/cholangiocellular carcinoma with sarcomatoid features: genetic analysis for histogenesis. Hepatol Res. 2001; 21: 220-227.
44. Sirica AE,. Role of ErbB family receptor tyrosine kinases in intrahepatic cholangiocarcinoma. World J Gastroenterol. 2008; 14: 7033-7058.
45. Endo K, Yoon BI, Pairojkul C, Demetris AJ, Sirica AE,. ERBB-2 overexpression and cyclooxygenase-2 up-regulation in human cholangiocarcinoma and risk conditions. Hepatology. 2002; 36: 439-450.
46. Sirica AE, Lai GH, Endo K, Zhang Z, Yoon BI,. Cyclooxygenase-2 and ERBB-2 in cholangiocarcinoma: potential therapeutic targets. Semin Liver Dis. 2002; 22: 303-313.
47. Goldenberg D, Rosenbaum E, Argani P, Wistuba II, Sidransky D, Thuluvath PJ, et-al. The V599E BRAF mutation is uncommon in biliary tract cancers. Mod Pathol. 2004; 17: 1386-1391.
48. Tannapfel A, Sommerer F, Benicke M, Katalinic A, Uhlmann D, Witzigmann H, et-al. Mutations of the BRAF gene in cholangiocarcinoma but not in hepatocellular carcinoma. Gut. 2003; 52: 706-712.
49. Riener MO, Bawohl M, Clavien PA, Jochum W,. Rare PIK3CA hotspot mutations in carcinomas of the biliary tract. Genes Chromosomes Cancer. 2008; 47: 363-367.
50. Xu RF, Sun JP, Zhang SR, Zhu GS, Li LB, Liao YL, et-al. KRAS and PIK3CA but not BRAF genes are frequently mutated in Chinese cholangiocarcinoma patients. Biomed Pharmacother. 2011; 65: 22-26.
51. Chan-On W, Nairismagi ML, Ong CK, Lim WK, Dima S, Pairojkul C, et-al. Exome sequencing identifies distinct mutational patterns in liver fluke-related and non-infection-related bile duct cancers. Nat Genet. 2013; 45: 1474-1478.
52. Kubicka S, Kuhnel F, Flemming P, Hain B, Kezmic N, Rudolph KL, et-al. K-ras mutations in the bile of patients with primary sclerosing cholangitis. Gut. 2001; 48: 403-408.
53. Kamikawa T, Amenomori M, Itoh T, Momoi H, Hiai H, Machinami R, et-al. Analysis of genetic changes in intrahepatic cholangiocarcinoma induced by thorotrast. Radiat Res. 1999; 152 (6 Suppl): S118-124.
54. Khan SA, Thomas HC, Toledano MB, Cox IJ, Taylor-Robinson SD,. p53 Mutations in human cholangiocarcinoma: a review. Liver Int. 2005; 25: 704-716.
55. Borger DR, Tanabe KK, Fan KC, Lopez HU, Fantin VR, Straley KS, et-al. Frequent mutation of isocitrate dehydrogenase (IDH)1 and IDH2 in cholangiocarcinoma identified through broad-based tumor genotyping. Oncologist. 2012; 17: 72-79.
56. Kipp BR, Voss JS, Kerr SE, Barr Fritcher EG, Graham RP, Zhang L, et-al. Isocitrate dehydrogenase 1 and 2 mutations in cholangiocarcinoma. Hum Pathol. 2012; 43: 1552-1558.
57. Endo K, Ashida K, Miyake N, Terada T,. E-cadherin gene mutations in human intrahepatic cholangiocarcinoma. J Pathol. 2001; 193: 310-317.
58. Tokumoto N, Ikeda S, Ishizaki Y, Kurihara T, Ozaki S, Iseki M, et-al. Immunohistochemical and mutational analyses of Wnt signaling components and target genes in intrahepatic cholangiocarcinomas. Int J Oncol. 2005; 27: 973-980.
59. Ong CK, Subimerb C, Pairojkul C, Wongkham S, Cutcutache I, Yu W, et-al. Exome sequencing of liver fluke-associated cholangiocarcinoma. Nat Genet. 2012; 44: 690-693.
60. Jiao Y, Pawlik TM, Anders RA, Selaru FM, Streppel MM, Lucas DJ, et-al. Exome sequencing identifies frequent inactivating mutations in BAP1, ARID1A and PBRM1 in intrahepatic cholangiocarcinomas. Nat Genet. 2013; 45: 1470-1473.
61. Gao Q, Zhao YJ, Wang XY, Guo WJ, Gao S, Wei L, et-al. Activating mutations in PTPN3 promote cholangiocarcinoma cell proliferation and migration and are associated with tumor recurrence in patients. Gastroenterology. 2014; 146: 1397-1407.
62. Guichard C, Amaddeo G, Imbeaud S, Ladeiro Y, Pelletier L, Maad IB, et-al. Integrated analysis of somatic mutations and focal copy-number changes identifies key genes and pathways in hepatocellular carcinoma. Nat Genet. 2012; 44: 694-698.
63. Huang Q, Lin B, Liu H, Ma X, Mo F, Yu W, et-al. RNA-Seq analyses generate comprehensive transcriptomic landscape and reveal complex transcript patterns in hepatocellular carcinoma. PLoS ONE. 2011; 6: e26168.
64. Morris LG, Taylor BS, Bivona TG, Gong Y, Eng S, Brennan CW, et-al. Genomic dissection of the epidermal growth factor receptor (EGFR)/PI3K pathway reveals frequent deletion of the EGFR phosphatase PTPRS in head and neck cancers. Proc Natl Acad Sci USA. 2011; 108: 19024-19029.
65. Ross JS, Wang K, Gay L, Al-Rohil R, Rand JV, Jones DM, et-al. New routes to targeted therapy of intrahepatic cholangiocarcinomas revealed by next-generation sequencing. Oncologist. 2014; 19: 235-242.
66. Wu YM, Su F, Kalyana-Sundaram S, Khazanov N, Ateeq B, Cao X, et-al. Identification of targetable FGFR gene fusions in diverse cancers. Cancer Discov. 2013; 3: 636-647.
67. Arai Y, Totoki Y, Hosoda F, Shirota T, Hama N, Nakamura H, et-al. Fibroblast growth factor receptor 2 tyrosine kinase fusions define a unique molecular subtype of cholangiocarcinoma. Hepatology. 2014; 59: 1427-1434.
68. Borad MJ, Champion MD, Egan JB, Liang WS, Fonseca R, Bryce AH, et-al. Integrated genomic characterization reveals novel, therapeutically relevant drug targets in FGFR and EGFR pathways in sporadic intrahepatic cholangiocarcinoma. PLoS Genet. 2014; 10: e1004135.
69. Graham RP, Barr Fritcher EG, Pestova E, Schulz J, Sitailo LA, Vasmatzis G, et-al. Fibroblast growth factor receptor 2 translocations in intrahepatic cholangiocarcinoma. Hum Pathol. 2014; 45: 1630-1638.
70. Baylin SB, Herman JG,. DNA hypermethylation in tumorigenesis: epigenetics joins genetics. Trends Genet. 2000; 16: 168-174.
71. Jones PA, Laird PW,. Cancer epigenetics comes of age. Nat Genet. 1999; 21: 163-167.
72. Isomoto H,. Epigenetic alterations associated with cholangiocarcinoma (review). Oncol Rep. 2009; 22: 227-232.
73. Sandhu DS, Shire AM, Roberts LR,. Epigenetic DNA hypermethylation in cholangiocarcinoma: potential roles in pathogenesis, diagnosis and identification of treatment targets. Liver Int. 2008; 28: 12-27.
74. Kim BH, Cho NY, Choi M, Lee S, Jang JJ, Kang GH,. Methylation profiles of multiple CpG island loci in extrahepatic cholangiocarcinoma versus those of intrahepatic cholangiocarcinomas. Arch Pathol Lab Med. 2007; 131: 923-930.
75. Lee S, Kim WH, Jung HY, Yang MH, Kang GH,. Aberrant CpG island methylation of multiple genes in intrahepatic cholangiocarcinoma. Am J Pathol. 2002; 161: 1015-1022.
76. Tannapfel A, Sommerer F, Benicke M, Weinans L, Katalinic A, Geissler F, et-al. Genetic and epigenetic alterations of the INK4a-ARF pathway in cholangiocarcinoma. J Pathol. 2002; 197: 624-631.
77. Yang B, House MG, Guo M, Herman JG, Clark DP,. Promoter methylation profiles of tumor suppressor genes in intrahepatic and extrahepatic cholangiocarcinoma. Mod Pathol. 2005; 18: 412-420.
78. Isomoto H, Mott JL, Kobayashi S, Werneburg NW, Bronk SF, Haan S, et-al. Sustained IL-6/STAT-3 signaling in cholangiocarcinoma cells due to SOCS-3 epigenetic silencing. Gastroenterology. 2007; 132: 384-396.
79. Wong N, Li L, Tsang K, Lai PB, To KF, Johnson PJ,. Frequent loss of chromosome 3p and hypermethylation of RASSF1A in cholangiocarcinoma. J Hepatol. 2002; 37: 633-639.
80. Andersen JB, Factor VM, Marquardt JU, Raggi C, Lee YH, Seo D, et-al. An integrated genomic and epigenomic approach predicts therapeutic response to zebularine in human liver cancer. Sci Transl Med. 2010; 2: 54ra77.
81. Bird A,. DNA methylation patterns and epigenetic memory. Genes Dev. 2002; 16: 6-21.
82. Cheng JC, Yoo CB, Weisenberger DJ, Chuang J, Wozniak C, Liang G, et-al. Preferential response of cancer cells to zebularine. Cancer Cell. 2004; 6: 151-158.
83. Pinto A, Zagonel V,. 5-Aza-2′-deoxycytidine (Decitabine) and 5-azacytidine in the treatment of acute myeloid leukemias and myelodysplastic syndromes: past, present and future trends. Leukemia. 1993; 7 (Suppl): 151-160.
84. Sriraksa R, Zeller C, El-Bahrawy MA, Dai W, Daduang J, Jearanaikoon P, et-al. CpG-island methylation study of liver fluke-related cholangiocarcinoma. Br J Cancer. 2011; 104: 1313-1318.
85. Sriraksa R, Zeller C, Dai W, Siddiq A, Walley AJ, Limpaiboon T, et-al. Aberrant DNA methylation at genes associated with a stem cell-like phenotype in cholangiocarcinoma tumors. Cancer Prev Res (Phila). 2013; 6: 1348-1355.
86. Goeppert B, Konermann C, Schmidt CR, Bogatyrova O, Geiselhart L, Ernst C, et-al. Global alterations of DNA methylation in cholangiocarcinoma target the Wnt signaling pathway. Hepatology. 2014; 59: 544-554.
87. Turcan S, Rohle D, Goenka A, Walsh LA, Fang F, Yilmaz E, et-al. IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype. Nature. 2012; 483: 479-483.
88. Huang L, Frampton G, Liang LJ, Demorrow S,. Aberrant DNA methylation profile in cholangiocarcinoma. World J Gastrointest Pathophysiol. 2010; 1: 23-29.
89. Ahrendt SA, Eisenberger CF, Yip L, Rashid A, Chow JT, Pitt HA, et-al. Chromosome 9p21 loss and p16 inactivation in primary sclerosing cholangitis-associated cholangiocarcinoma. J Surg Res. 1999; 84: 88-93.
90. Isomoto H, Kobayashi S, Werneburg NW, Bronk SF, Guicciardi ME, Frank DA, et-al. Interleukin 6 upregulates myeloid cell leukemia-1 expression through a STAT3 pathway in cholangiocarcinoma cells. Hepatology. 2005; 42: 1329-1338.
91. Kobayashi S, Werneburg NW, Bronk SF, Kaufmann SH, Gores GJ,. Interleukin-6 contributes to Mcl-1 up-regulation and TRAIL resistance via an Akt-signaling pathway in cholangiocarcinoma cells. Gastroenterology. 2005; 128: 2054-2065.
92. Wehbe H, Henson R, Meng F, Mize-Berge J, Patel T,. Interleukin-6 contributes to growth in cholangiocarcinoma cells by aberrant promoter methylation and gene expression. Cancer Res. 2006; 66: 10517-10524.
93. Budhu A, Ji J, Wang XW,. The clinical potential of microRNAs. J Hematol Oncol. 2010; 3: 37.
94. Wang XW, Heegaard NH, Orum H,. MicroRNAs in liver disease. Gastroenterology. 2012; 142: 1431-1443.
95. Coulouarn C, Factor VM, Andersen JB, Durkin ME, Thorgeirsson SS,. Loss of miR-122 expression in liver cancer correlates with suppression of the hepatic phenotype and gain of metastatic properties. Oncogene. 2009; 28: 3526-3536.
96. Lu J, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, Peck D, et-al. MicroRNA expression profiles classify human cancers. Nature. 2005; 435: 834-838.
97. Braconi C, Huang N, Patel T,. MicroRNA-dependent regulation of DNA methyltransferase-1 and tumor suppressor gene expression by interleukin-6 in human malignant cholangiocytes. Hepatology. 2010; 51: 881-890.
98. Meng F, Henson R, Lang M, Wehbe H, Maheshwari S, Mendell JT, et-al. Involvement of human micro-RNA in growth and response to chemotherapy in human cholangiocarcinoma cell lines. Gastroenterology. 2006; 130: 2113-2129.
99. Meng F, Wehbe-Janek H, Henson R, Smith H, Patel T,. Epigenetic regulation of microRNA-370 by interleukin-6 in malignant human cholangiocytes. Oncogene. 2008; 27: 378-386.
100. Mott JL, Kobayashi S, Bronk SF, Gores GJ,. mir-29 regulates Mcl-1 protein expression and apoptosis. Oncogene. 2007; 26: 6133-6140.
101. Stutes M, Tran S, DeMorrow S,. Genetic and epigenetic changes associated with cholangiocarcinoma: from DNA methylation to microRNAs. World J Gastroenterol. 2007; 13: 6465-6469.
102. Kawahigashi Y, Mishima T, Mizuguchi Y, Arima Y, Yokomuro S, Kanda T, et-al. MicroRNA profiling of human intrahepatic cholangiocarcinoma cell lines reveals biliary epithelial cell-specific microRNAs. J Nippon Med Sch. 2009; 76: 188-197.
103. Chen L, Yan HX, Yang W, Hu L, Yu LX, Liu Q, et-al. The role of microRNA expression pattern in human intrahepatic cholangiocarcinoma. J Hepatol. 2009; 50: 358-369.
104. Selaru FM, Olaru AV, Kan T, David S, Cheng Y, Mori Y, et-al. MicroRNA-21 is overexpressed in human cholangiocarcinoma and regulates programmed cell death 4 and tissue inhibitor of metalloproteinase 3. Hepatology. 2009; 49: 1595-1601.
105. Huang JL, Biehl TR, Lee FT, Zimmer PW, Ryan JA, Jr,. Outcomes after resection of cholangiocellular carcinoma. Am J Surg. 2004; 187: 612-617.
106. Qiu YH, Wei YP, Shen NJ, Wang ZC, Kan T, Yu WL, et-al. miR-204 inhibits epithelial to mesenchymal transition by targeting slug in intrahepatic cholangiocarcinoma cells. Cell Physiol Biochem. 2013; 32: 1331-1341.
107. Li B, Han Q, Zhu Y, Yu Y, Wang J, Jiang X,. Down-regulation of miR-214 contributes to intrahepatic cholangiocarcinoma metastasis by targeting Twist. FEBS J. 2012; 279: 2393-2398.
108. Sulpice L, Rayar M, Desille M, Turlin B, Fautrel A, Boucher E, et-al. Molecular profiling of stroma identifies Osteopontin as an independent predictor of poor prognosis in intrahepatic cholangiocarcinoma. Hepatology. 2013; 58: 1992-2000.
109. Kajiyama K, Maeda T, Takenaka K, Sugimachi K, Tsuneyoshi M,. The significance of stromal desmoplasia in intrahepatic cholangiocarcinoma: a special reference of "scirrhous-type" and "nonscirrhous-type" growth. Am J Surg Pathol. 1999; 23: 892-902.
110. DeClerck YA,. Desmoplasia: a response or a niche? Cancer Discov. 2012; 2: 772-774.
111. Schoffski P,. Polo-like kinase (PLK) inhibitors in preclinical and early clinical development in oncology. Oncologist. 2009; 14: 559-570.
112. Thrum S, Lorenz J, Mossner J, Wiedmann M,. Polo-like kinase 1 inhibition as a new therapeutic modality in therapy of cholangiocarcinoma. Anticancer Res. 2011; 31: 3289-3299.
113. Fingas CD, Mertens JC, Razumilava N, Sydor S, Bronk SF, Christensen JD, et-al. Polo-like kinase 2 is a mediator of hedgehog survival signaling in cholangiocarcinoma. Hepatology. 2013; 58: 1362-1374.
114. Berman DM, Karhadkar SS, Maitra A, Montes De Oca R, Gerstenblith MR, Briggs K, et-al. Widespread requirement for Hedgehog ligand stimulation in growth of digestive tract tumours. Nature. 2003; 425: 846-851.
115. Olive KP, Jacobetz MA, Davidson CJ, Gopinathan A, McIntyre D, Honess D, et-al. Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science. 2009; 324: 1457-1461.
116. Chuaysri C, Thuwajit P, Paupairoj A, Chau-In S, Suthiphongchai T, Thuwajit C,. Alpha-smooth muscle actin-positive fibroblasts promote biliary cell proliferation and correlate with poor survival in cholangiocarcinoma. Oncol Rep. 2009; 21: 957-969.
117. Choi SS, Omenetti A, Witek RP, Moylan CA, Syn WK, Jung Y, et-al. Hedgehog pathway activation and epithelial-to-mesenchymal transitions during myofibroblastic transformation of rat hepatic cells in culture and cirrhosis. Am J Physiol Gastrointest Liver Physiol. 2009; 297: G1093-1106.
118. Fingas CD, Bronk SF, Werneburg NW, Mott JL, Guicciardi ME, Cazanave SC, et-al. Myofibroblast-derived PDGF-BB promotes Hedgehog survival signaling in cholangiocarcinoma cells. Hepatology. 2011; 54: 2076-2088.
119. Fingas CD, Mertens JC, Razumilava N, Bronk SF, Sirica AE, Gores GJ,. Targeting PDGFR-beta in Cholangiocarcinoma. Liver Int. 2012; 32: 400-409.
120. Panman L, Galli A, Lagarde N, Michos O, Soete G, Zuniga A, et-al. Differential regulation of gene expression in the digit forming area of the mouse limb bud by SHH and gremlin 1/FGF-mediated epithelial-mesenchymal signalling. Development. 2006; 133: 3419-3428.
121. Xie G, Karaca G, Swiderska-Syn M, Michelotti GA, Kruger L, Chen Y, et-al. Cross-talk between notch and hedgehog regulates hepatic stellate cell fate. Hepatology. 2013; 58: 1801-1813.
122. Omenetti A, Popov Y, Jung Y, Choi SS, Witek RP, Yang L, et-al. The hedgehog pathway regulates remodelling responses to biliary obstruction in rats. Gut. 2008; 57: 1275-1282.
123. Ishimura N, Bronk SF, Gores GJ,. Inducible nitric oxide synthase up-regulates Notch-1 in mouse cholangiocytes: implications for carcinogenesis. Gastroenterology. 2005; 128: 1354-1368.
124. Chen Y, Zheng S, Qi D, Zheng S, Guo J, Zhang S, et-al. Inhibition of Notch signaling by a gamma-secretase inhibitor attenuates hepatic fibrosis in rats. PLoS ONE. 2012; 7: e46512.
125. Chang J, Hisamatsu T, Shimamura K, Yoneno K, Adachi M, Naruse H, et-al. Activated hepatic stellate cells mediate the differentiation of macrophages. Hepatol Res. 2013; 43: 658-669.
126. Meng F, Yamagiwa Y, Ueno Y, Patel T,. Over-expression of interleukin-6 enhances cell survival and transformed cell growth in human malignant cholangiocytes. J Hepatol. 2006; 44: 1055-1065.
127. Cheon YK, Cho YD, Moon JH, Jang JY, Kim YS, Kim YS, et-al. Diagnostic utility of interleukin-6 (IL-6) for primary bile duct cancer and changes in serum IL-6 levels following photodynamic therapy. Am J Gastroenterol. 2007; 102: 2164-2170.
128. Han C, Demetris AJ, Stolz DB, Xu L, Lim K, Wu T,. Modulation of Stat3 activation by the cytosolic phospholipase A2alpha and cyclooxygenase-2-controlled prostaglandin E2 signaling pathway. J Biol Chem. 2006; 281: 24831-24846.
129. Wu GS, Zou SQ, Liu ZR, Tang ZH, Wang JH,. Celecoxib inhibits proliferation and induces apoptosis via prostaglandin E2 pathway in human cholangiocarcinoma cell lines. World J Gastroenterol. 2003; 9: 1302-1306.
130. Wu T, Leng J, Han C, Demetris AJ,. The cyclooxygenase-2 inhibitor celecoxib blocks phosphorylation of Akt and induces apoptosis in human cholangiocarcinoma cells. Mol Cancer Ther. 2004; 3: 299-307.
131. Hedvat M, Huszar D, Herrmann A, Gozgit JM, Schroeder A, Sheehy A, et-al. The JAK2 inhibitor AZD1480 potently blocks Stat3 signaling and oncogenesis in solid tumors. Cancer Cell. 2009; 16: 487-497.
132. Scuto A, Krejci P, Popplewell L, Wu J, Wang Y, Kujawski M, et-al. The novel JAK inhibitor AZD1480 blocks STAT3 and FGFR3 signaling, resulting in suppression of human myeloma cell growth and survival. Leukemia. 2011; 25: 538-550.
133. Ramos A, Camargo FD,. The Hippo signaling pathway and stem cell biology. Trends Cell Biol. 2012; 22: 339-346.
134. Lee KP, Lee JH, Kim TS, Kim TH, Park HD, Byun JS, et-al. The Hippo-Salvador pathway restrains hepatic oval cell proliferation, liver size, and liver tumorigenesis. Proc Natl Acad Sci USA. 2010; 107: 8248-8253.
135. Zhou D, Conrad C, Xia F, Park JS, Payer B, Yin Y, et-al. Mst1 and Mst2 maintain hepatocyte quiescence and suppress hepatocellular carcinoma development through inactivation of the Yap1 oncogene. Cancer Cell. 2009; 16: 425-438.
136. Avruch J, Zhou D, Fitamant J, Bardeesy N,. Mst1/2 signalling to Yap: gatekeeper for liver size and tumour development. Br J Cancer. 2011; 104: 24-32.
137. Chiang J, Martinez-Agosto JA,. Effects of mTOR inhibitors on components of the salvador-warts-hippo pathway. Cells. 2012; 1: 886-904.